Cingi, CemalBayar Muluk, NurayUlusoy, SeckinAcar, MustafaSirin, SeherCobanoglu, BenguBal, Cengiz2020-06-252020-06-252015closedAccess0937-44771434-4726https://doi.org/10.1007/s00405-014-3444-1https://hdl.handle.net/20.500.12587/6025BAL, Cengiz/0000-0002-1553-2902; Sirin, Seher/0000-0002-2982-9379In the present study, we investigated the outcomes of sublingual immunotherapy (SLIT) in house dust mite-induced allergic rhinitis (HDM-AR) patients. In this prospective, multicentric study, 186 patients with AR who had positive skin prick test results for HDMs were included. The patients were administered SLIT using Staloral 300 for 1 year. Evaluation of the patients regarding symptom scores, clinical findings and Rhinitis Quality of Life Questionnaire (RQLQ) scores was performed at baseline, and then at 6 and 12 months of therapy. Our results showed that, for all of the evaluated items (symptom scores, clinical findings and RQLQ scores), 12-month values were significantly lower than those at 6 months and baseline. Similarly, 6-month values were significantly lower than those at baseline. There were no complications in any of our patients. SLIT for HDM-AR is a treatment modality that can be used safely. We obtained better results than expected, and the treatment showed a positive psychological effect; the patients believed that SLIT was the final step of treatment and, which made them feel better.eninfo:eu-repo/semantics/closedAccessSublingual immunotherapy (SLIT)Allergic rhinitis (AR)Rhinitis Quality of Life Questionnaire (RQLQ)House dust mite (HDM)Article272113341334610.1007/s00405-014-3444-12-s2.0-8494215463725516223Q1WOS:000361540600036Q2